Tenaya Therapeutics, Inc. (TNYA): Price and Financial Metrics

Tenaya Therapeutics up 6% following director stock purchase

• Tenaya Therapeutics (NASDAQ:TNYA) is up ~6% in after-hours trading on Thursday after a member of the board of directors made a large acquisition of additional shares.
• David Goeddel, managing partner at The Column Group, bought 49,463 shares on Jan. 17 at an average price of $2.49 per share, and another 135,688 shares on Jan. 18 at an average $2.52 per share.
• The shares are directly held by The Column Group, who in total own ~5M shares, according to a Seeking Alpha | January 19, 2023

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 Cash Runway Extended into First Half 2025 SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and

Yahoo | January 9, 2023

Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop

The recent price decline of 23% in Tenaya Therapeutics, Inc.'s ( NASDAQ:TNYA ) stock may have disappointed insiders who...

Yahoo | December 21, 2022

Tenaya Therapeutics Inc. (NASDAQ:TNYA) Adds 8.49% In A Week: What’s Lifting The Stock?

In last trading session, Tenaya Therapeutics Inc. (NASDAQ:TNYA) saw 0.49 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.30 trading at -$0.07 or -2.95% at ring of the bell on the day assigns it a market valuation of $158.93M. That closing price of TNYA’s stock is … Tenaya Therapeutics Inc. (NASDAQ:TNYA) Adds 8.49% In A Week: What’s Lifting The Stock? Read More »

Marketing Sentinel | December 17, 2022

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases.

GlobeNewswire | December 7, 2022